Proteasome inhibitors as reversers of resistance to artemisinin-based antimalarials

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1092808

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Current antimalarial control is highly dependent on Artemisinin Combination Therapy (ACTs), which makes recent reports of decreased clinical efficacy of artemisinins extremely concerning. This project will develop proteasome inhibitors to synergise the activity of artemisinins - effectively reversing resistance. We will confirm that the selected compounds have good bioavailability, low cytotoxicity in human cell lines and efficacy in mouse models of malaria.

Funded Activity Details

Start Date: 01-01-2015

End Date: 01-01-2017

Funding Scheme: Development Grants

Funding Amount: $473,534.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Medical Parasitology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cancer chemotherapeutic agents | drug interactions | malaria drug resistance | malaria therapy | myeloma

Related Links